Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O76082
UPID:
OCTN2_HUMAN
Alternative names:
High-affinity sodium-dependent carnitine cotransporter; Solute carrier family 22 member 5
Alternative UPACC:
O76082; A2Q0V1; B2R844; D3DQ87; Q6ZQZ8; Q96EH6
Background:
Organic cation/carnitine transporter 2, also known as the high-affinity sodium-dependent carnitine cotransporter and solute carrier family 22 member 5, plays a crucial role in the active cellular uptake of carnitine. It transports sodium ions with carnitine molecules, facilitating the transport of organic cations and contributing to intestinal homeostasis and testis blood-barrier regulation.
Therapeutic significance:
Systemic primary carnitine deficiency, a disorder of fatty acid oxidation due to defective carnitine transport, highlights the protein's clinical relevance. Understanding the role of Organic cation/carnitine transporter 2 could open doors to potential therapeutic strategies for treating metabolic decompensation, skeletal myopathy, and cardiomyopathy.